Oncternal Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization medicines to treat medical conditions, including stress urinary incontinence and prostate cancer. Co. is focused on the further development of selective androgen receptor modulators (SARMs), including its primary product candidate, enobosarm (GTx-024). SARMs is a class of drugs that has the potential to treat serious medical conditions such as stress urinary incontinence. Co. is also evaluating enobosarm and other compounds in its SARM portfolio for indications outside of oncology. We show 12 historical shares outstanding datapoints in our coverage of GTXI's shares outstanding history.
Understanding the changing numbers of GTXI shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like GTXI versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching GTXI by allowing them to research GTXI shares outstanding history
as well as any other stock in our coverage universe. |
Free GTXI Email Alerts:
Video: Shares Outstanding Importance
